Research Article

DNA Methylation Profiles of the DRD2 and NR3C1 Genes in Patients with Recent-Onset Psychosis

Yan Hong Piao,1,2 Yin Cui,3 Ling Li,1,2 Maryam Karamikheirabad,1,2 Sung-Wan Kim,4 Bong Ju Lee,1,2 Jung Jin Kim,6 Je-Chun Yu,7 Kyu Young Lee,8 Seung-Hee Won,9 Seung-Hwan Lee,10 Seung-Hyun Kim,11 Shi Hyun Kang,12 Euitae Kim,13 Nam-In Kang,14 Fatima Zahra Rami,1,2 and Young-Chul Chung1,2

1Department of Psychiatry, Jeonbuk National University Medical School, Jeonju, Republic of Korea
2Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea
3Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4Department of Psychiatry, Chonnam National University Medical School, Gwangju, Republic of Korea
5Department of Psychiatry, Inje University Haedundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea
6Department of Psychiatry, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, Republic of Korea
7Department of Psychiatry, Eulji University School of Medicine, Eulji University Hospital, Daegu, Republic of Korea
8Department of Psychiatry, Nowon Eulji Medical Center, Eulji University, Seoul, Republic of Korea
9Department of Psychiatry, Kyungpook National University School of Medicine, Daegu, Republic of Korea
10Department of Psychiatry, Inje University Ilsan Paik Hospital, Goyang, Republic of Korea
11Department of Psychiatry, Korea University College of Medicine, Guro Hospital, Seoul, Republic of Korea
12Department of Social Psychiatry and Rehabilitation, National Center for Mental Health, Seoul, Republic of Korea
13Department of Psychiatry, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
14Department of Psychiatry, Maeumsarang Hospital, Wanju, Jeollabuk-do, Republic of Korea

Correspondence should be addressed to Young-Chul Chung; chungyc@jbnu.ac.kr

Received 6 February 2022; Revised 25 May 2022; Accepted 14 July 2022; Published 3 August 2022

Academic Editor: Helge Frieling

Copyright © 2022 Yan Hong Piao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. Dopamine receptor D2 gene (DRD2) and glucocorticoid receptor gene (NR3C1) are implicated in the development of psychosis. We investigated methylation levels of DRD2 and NR3C1 in peripheral blood of patients with recent-onset (RO) psychosis using bisulfite pyrosequencing as well as its association with childhood trauma and rumination.

Methods. In all, 51 individuals with RO psychosis and 47 healthy controls were recruited. DNA methylation levels in the targeted regions of two genes were analyzed and compared. Childhood trauma and rumination were evaluated using the Early Trauma Inventory Self-Report Short Form (ETI-SF) and Brooding Scale (BS), respectively. Correlations between the scores of the ETI-SF and BS and methylation levels were explored.

Results. For DRD2, we found no significant differences between groups in terms of methylation level or association with childhood trauma or rumination. For NR3C1, we found a trend level significance for average value of all CpG sites and significant hypermethylation or hypomethylation at specific sites. There was also a significant positive correlation between the methylation level at the CpG8 site of NR3C1 exon 1F and negative symptom subscale score of the PANSS (PANSS-N).

Conclusion. Epigenetic alterations of NR3C1 are associated with the pathophysiology of psychosis. Further epigenetic studies will elucidate the molecular mechanisms underpinning the pathophysiology of psychosis.
1. Introduction

Schizophrenia (SZ) is a complex disorder with genetic and environmental liabilities. A recent genome-wide association study of SZ revealed 108 loci associated with the disease [1]. However, the proportion of the variance in liability explained by single nucleotide polymorphisms (SNP) is small; significant genomewide loci explain only 3.4% of the variance in liability, and the cumulative effect of common loci explained as a polygenic risk score is estimated to explain 7% [2]. Epigenetic studies in SZ are crucial because they can elucidate how the environment affects the genetic structure of SZ. Furthermore, altered epigenetic markers can be modified by pharmaceutical and psychosocial interventions. DNA methylation, which occurs almost exclusively at CpG dinucleotides, is the most frequently studied epigenetic mechanism. DNA methylation studies generally use changes in methylation from peripheral blood cells of SZ patients at genes such as HTR1A [3], S-COMT [4], BDNF promoter I [5], HTR1E and COMTD1 [6], and MB-COMT [7].

The genes of interest in our study were the dopamine receptor D2 gene (DRD2) and glucocorticoid receptor gene (NR3C1). Although there is a strong association between the roles of DRD2 and NR3C1 and the development of SZ, only a few reports about DNA methylation in these genes using peripheral leukocytes have been published. Studies on DNA methylation of DRD2 have reported mixed results, including no signiﬁcant diﬀerence [8] or lower methylation rates [9–11] compared to healthy controls. For NR3C1, results have varied depending on which CpG sites or components were analyzed, e.g., hypomethylation at 1D-CpG8 and hypermethylation at 1B–CpG15 and 1F–CpG21 [12] and hypomethylation or hypermethylation at component 2, including 5 CpG sites, depending on the stage of psychosis [13]. Previous studies have been limited because subjects were mainly chronic SZ patients and clinical correlates were not investigated adequately.

We investigated the association between DRD2 and NR3C1 methylation rates and childhood trauma and rumination. There is a clear link between SZ and exposure to childhood trauma [14]. Childhood trauma leads to hypothalamic–pituitary–adrenal (HPA) hyperactivity via methylation of the NR3C1 gene, which represses NR3C1 transcription [15, 16]. Rumination, a repetitive and negatively balanced mode of thinking, has been implicated in the development of depression [17], negative [18] and positive symptoms [19], and suicidality [20] in SZ. A close correlation between childhood trauma and rumination has also been reported [21]. We hypothesized that there might be altered methylation of NR3C1 in psychosis, which in turn is associated with childhood trauma and rumination. The present study examined methylation rates of DRD2 and NR3C1 in patients with recent-onset (RO) psychosis using bisulfite pyrosequencing as well as its association with childhood trauma and rumination.

2. Methods

2.1. Participants. To be considered for inclusion, subjects were required to be between 19 and 59 years of age and meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [22] criteria for SZ spectrum and other psychotic disorders (SZ, schizophreniform disorder, other specified SZ spectrum and other psychotic disorders (OSSEO), brief psychotic disorder, and delusional disorder). RO was defined as duration of illness ≤2 years. The exclusion criteria were intelligence quotient < 70, history of head trauma, serious neurological disorder (epilepsy, stroke, Parkinson’s disease, and/or dementia), and significant medical illness. Participants were recruited from the Korean Early Psychosis Cohort Study (KEPS), a nationwide, multicenter, prospective, and naturalistic observational study. Age- and sex-matched healthy individuals were recruited for the control group via advertisements. All participants provided written informed consent in accordance with a protocol approved by the ethics committee of the Jeonbuk National University Hospital (approval number CUH 2014–11–002).

2.2. Clinical Assessment. The severity of symptoms was evaluated within a week of blood sampling using the Positive and Negative Syndrome Scale (PANSS) [23, 24] and Calgary Depression Scale for Schizophrenia (CDSS) [25, 26]. The self-rating scales employed were the Brooding Scale (BS) [27] and Early Trauma Inventory Self-Report Short Form (ETI-SF) [28]. Data for factors related to lifestyle were obtained using the Fagerstrom Test for Nicotine Dependence (FTND) [29], Alcohol Use Disorders Identification Test (AUDIT) [30], Dietary Habits Questionnaire (DHQ) [31], and Physical Activity Rating (PA-R) [32]. For simplicity, we used only the fourth item of the FTND (0, nonsmoker; 1, ≤10 cigarettes/day; 2, 11–20 cigarettes/day; 3, 21–30 cigarettes/day; and 4, ≥31 cigarettes/day) and the mean of items 1 and 2 from the AUDI, i.e., (sum of the scores on items 1 and 2)/2. The DHQ is a 20-item, self-administered questionnaire consisting of three subcategories: five items for diet regularity, six items for a balanced diet, and nine items for an unhealthy diet and eating habits. This scale was developed based on dietary guidance published by the Korean Ministry for Health, Welfare, and Family Affairs (2010). Each item is scored on a three-point scale (1, 3, and 5 points) according to the frequency of the dietary habit. Higher scores indicate better dietary habits in the respective categories. The PA-R is a questionnaire for rating a person’s level of physical activity, with scores ranging from 0 (avoids walking or exercise) to 7 (runs more than 10 miles per week or spends more than 3 h per week in comparable physical activity).

2.3. DNA Extraction and Bisulfite Modification. Genomic DNA was extracted from the collected peripheral blood mononuclear cell samples using a QIAGEN DNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. All prepared samples were bisulfite-converted according to the EZ DNA Methylation Kit protocols (Zymo Research, Irvine, CA, USA).

2.4. Bisulfite Pyrosequencing. DNA methylation was measured by pyrosequencing the polymerase chain reaction (PCR) products. Primers were designed against the putative promoter and first intron regions of DRD2, which were located from −50,955 bp to −50,382 bp of the translation start site (TSS) (chr11: 113,475,034–113,475,034) (Figure 1). A primer was designed against the exon 1f region of NR3C1, which
was located from –3,285 bp to –3,217 bp of the TSS (chr5:143,404,124–143,404,057) [33] (Figure 1). Several 800–900 bp regions were initially designed using PyroMark Assay Design 2.0 software (QIAGEN). Then, key regions, i.e., those that had more transcription factor binding sites, were selected using the JASPAR database version 8 (http://jaspar.genereg.net/) [34]. Details about the PCR primers and sequencing primer are shown in Table S1. Next, 40 ng bisulfite-treated DNA was amplified in a 25 μL reaction volume using the GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA, USA). Either the forward or reverse primer was biotinylated to convert the PCR product into single-stranded DNA templates, and then a sequencing primer that annealed to the single-stranded DNA template was added [35]. The PCR amplification step consisted of 45 cycles of 94°C for 30 s, 56°C for 30 s, and 72°C for 30 s; the primer sets, locations, and PCR conditions for each region are presented in Table S1. The pyrosequencing reactions were performed in a PyroMark Q48 Autoprep system (QIAGEN), and quantification of the CpG methylation (percentage of the relative light unit [RLU] of the C peak [methylated cytosine]/RLU of C peak + T peak [unmethylated cytosine]) was performed with PyroMark Q48 Autoprep 2.4.2 software (QIAGEN). When the peak value of a base exceeded 20 RLU, the pyrosequencing results were considered reliable.

2.5. Statistical Analysis. The assumption of normality for demographic and clinical characteristics was checked using the Shapiro–Wilk test. Because the data were not normally distributed, comparisons of demographic and clinical variables between the two groups were performed using the Mann–Whitney U test. Given the associations between educational attainment and DNA methylation [36], methylation rates between the two groups were compared using rank analyses of covariance with education as the covariate. Correlations between methylation rate and clinical parameters were explored using partial Spearman’s rank correlation with age, sex, or chlorpromazine (CPZ) equivalent dose as covariates. Separate analyses were performed to evaluate the relationships between methylation rates and age or CPZ equivalent dose. In addition, subgroup analyses with antipsychotic-naïve plus antipsychotic-free patients, schizophrenia spectrum disorder (SSD consisting of SZ and schizophreniform disorder), or OSSO were conducted. In subgroup analyses, methylation rates between the two groups were compared using rank analyses of covariance with age and education as covariate.
Comparison of methylation rates between the gender was also performed. Statistical significance was defined at the 95% level (p < 0.05). False discovery rate (FDR) corrections were used to limit type I error due to multiple comparisons.

### 3. Results

Demographic and clinical characteristics of the participants (51 patients with RO psychosis and 47 controls) are described in Table 1. Diagnoses included SZ (29.51%), schizophreniaform disorder (31.15%), OSSO (22.95%), brief psychotic disorder (9.84%), and delusional disorder (6.56%). The education levels of the two groups differed significantly. The methylation rates of DRD2 are shown in Table 2. We found significant differences in DRD2 methylation between the two groups at CpG5 (p = 0.01) and CpG6 (p = 0.045) based on uncorrected p values. However, there were no significant CpG sites after FDR correction (Table 2). The results were the same as with subgroup analyses, i.e., SSD vs. controls and OSSO vs. controls (Table S2-3). We also found significant (p ≤ 0.001 unless otherwise noted) differences (uncorrected p value) for NR3C1 methylation rate between the two groups at CpG1 (p = 0.014), CpG2, CpG4, CpG5 (p = 0.018), CpG6, CpG7, and CpG8. The average values of all CpG sites showed trend level significance between the patient and control groups. The average values were less than 5% regardless of diagnosis. The results were the same after FDR correction (Figure 2 and Table S4). In the subgroup analysis, results with SSD vs. controls were exactly the same (Table S5). However, results with OSSO vs. controls were different in that significant differences were found only at CpG1, CpG2, and CpG4 (Table S6). In gender subgroup analyses, we found no significant FDR corrected p values for both genes in patient and control groups (Table S7-10).

We found no significant partial correlations (FDR corrected) between DRD2 methylation rate and clinical parameters.
in the patient group adjusted for age, sex, and CPZ equivalent. However, at the uncorrected p value, there were significant correlations of several CpG sites with the emotional abuse subscale score of the ETI-SF (ETI-SF-E), BS, and positive symptom subscale score of the PANSS (PANSS-P) (Table S11). For NR3C1, significant positive correlation was found only between the CpG5 and negative symptom subscale score of the PANSS (PANSS-N) (r = 0.416, FDR = 0.033) (Figure 3 and Table 3). Several other CpG sites were also significantly associated with the PANSS-N using the uncorrected p value (Table S12). Furthermore, in antipsychotic-naive and -free patients, we found significant positive correlations between methylation rates of DRD2 and cognitive subscale and total scores of the BS (BS-C and BS-T) and ETI-SF-E in patients (Table S13).

Table 2: Comparison of methylation rate of DRD2 between patients and controls.

| CpG sites | Patient (n = 48–51) | Control (n = 41–47) | F (df) | p valuea | p valueb |
|-----------|---------------------|---------------------|--------|----------|----------|
| CpG1      | 24 ± 3.9            | 22.8 ± 2.9          | 1.013 (1, 96) | 0.317    | 0.494    |
| CpG2      | 33.6 ± 4.4          | 31.8 ± 2.9          | 1.626 (1, 96) | 0.205    | 0.452    |
| CpG3      | 10.8 ± 2.7          | 9.7 ± 1.4           | 0.766 (1, 95) | 0.384    | 0.494    |
| CpG4      | 12.4 ± 2.8          | 11.2 ± 1.6          | 3.725 (1, 87) | 0.057    | 0.213    |
| CpG5      | 5.4 ± 1.3           | 5.9 ± 1.3           | 6.923 (1, 96) | 0.010*   | 0.149    |
| CpG6      | 5.2 ± 1.1           | 5.3 ± 1.1           | 4.116 (1, 96) | 0.045*   | 0.213    |
| CpG7      | 4.6 ± 1.1           | 4.6 ± 0.7           | 2.117 (1, 96) | 0.149    | 0.447    |
| CpG8      | 4.3 ± 0.9           | 4.4 ± 0.8           | 3.832 (1, 96) | 0.053    | 0.213    |
| CpG9      | 11.7 ± 3.4          | 10.7 ± 1.7          | 0.298 (1, 96) | 0.586    | 0.628    |
| CpG10     | 16.6 ± 3.2          | 15.9 ± 2.1          | 0.730 (1, 96) | 0.395    | 0.494    |
| CpG11     | 16.3 ± 3.3          | 15.4 ± 1.7          | 0.949 (1, 96) | 0.332    | 0.494    |
| CpG12     | 18.4 ± 2.0          | 17.6 ± 1.3          | 0.470 (1, 96) | 0.495    | 0.571    |
| CpG13     | 11.8 ± 3.0          | 11.1 ± 1.4          | 0.948 (1, 96) | 0.333    | 0.494    |
| CpG14     | 5.3 ± 1.5           | 4.9 ± 0.7           | 1.586 (1, 96) | 0.211    | 0.452    |
| Mean      | 12.8 ± 2.0          | 12.2 ± 1.02         | 0.179 (1, 87) | 0.674    | 0.674    |

*aUncorrected p value. bFalse discovery rate adjusted p value. cRanked ANCOVA: a statistic controlling for the potential confounding effects of education. * < 0.05, ** < 0.01, and *** < 0.001.

Figure 2: Comparison of methylation rate of NR3C1 between patients and controls.
In the control group adjusted for age and sex, DRD2 methylation rates at CpG11 and CpG13 had significant negative partial correlations (FDR corrected) with BS-C \((r = -0.432, \text{FDR} = 0.045\) and \(r = -0.45, \text{FDR} = 0.045\), respectively) (Table 4). Using the uncorrected \(p\) value, we found significant correlations for several CpG sites with the ETI-SF and BS (Table S14). For NR3C1, we found no significant correlations using FDR corrected \(p\) values; however, we found significant correlations between CpG4 and the ETI-SF-S and BS-C using the uncorrected \(p\) values (Table S15). There were significant positive correlations between the age and average DRD2 methylation rates as well as with several specific rates in both patients and controls (Figure 4 and Table S16-17). We found no significant correlations between age and NR3C1 methylation rate in patients or controls (Table S18-19) or between CPZ equivalent dose in patients and methylation rate for either DRD2 or NR3C1.

**4. Discussion**

Epigenetics may provide a promising complement to psychosis studies of DNA sequence variation. It could shed light on how environmental factors affect gene expression and elucidate the pathophysiology of psychosis. We investigated DNA methylation rates at two candidate regions (DRD2 and NR3C1) in patients with RO psychosis and healthy controls. The associations between gene methylation rates and childhood trauma and rumination were also explored.

We found no significant differences (FDR corrected) in DRD2 between groups in contrast with previous studies [9–11]. In two previous studies [9, 11], the target region of DRD2 differed (only the CpG3, CpG4, CpG5, and CpG6 sites overlapped with CpG1, CpG2, CpG3, and CpG4 used in the present study). Moreover, participants were older with chronic SZ and took higher CPZ equivalent doses than patients in the present study. Kordi-Tamandani et al. [10] used methylation-specific PCR instead of pyrosequencing and reported only the global methylation rate. Therefore, our results cannot be compared directly to those of three previous studies reporting lower methylation rate of DRD2 in patients compared to controls [9–11]. It could be speculated that methylation status of DRD2 may be different at different stages of illness in psychosis. Considering significant correlations of age with methylation rate of DRD2 in both patient and control groups, we further performed the same analysis with age being added as a covariate. However, results were the same. In addition, no significant correlations with clinical parameters were reported. These results may have been caused by differences in the stages of psychosis or target regions of DRD2. Alternatively, medication may have affected the results although it was controlled as a covariate. This explanation is supported by the analyses of antipsychotic-naïve and -free patients. Finally, DRD2 methylation rate in the blood may not accurately reflect the status of methylation in the brain. Unexpectedly, we found significant negative correlations between the DRD2 methylation rates at CpG11 and CpG13 and BS-C in the control group. Because the control group had a significantly lower BS score than the patient group, the implication of this finding remains unclear.

For NR3C1, we found a trend level significance for average value of all CpG sites. Furthermore, significant hypermethylation or hypomethylation at specific sites was observed. This suggests that different CpG loci of NR3C1 may participate in psychosis through different regulatory mechanisms. We know of only two studies that measured DNA methylation of NR3C1 in SZ. One Chinese study reported no significant difference for the average value of CpG sites covering region 1F between patients with SZ and controls [12]. However, patients had significantly higher DNA methylation at CpG21 than controls. Different target regions (−3,285 to −3,487 relative to TSS) than ours (−3,217 to −3,285 relative to TSS) were also used. Furthermore, patients were much older than in our study, and the severity of symptoms was not provided. A Western study found that patients with first-episode psychosis (FEP) had significantly lower methylation of component 2.
Table 3: Correlation between methylation rate of NR3C1 and clinical parameters in patients.

| CpG sites | BS-E (n=48) | BS-C (n=48) | BS-T (n=48) | ETI-SF-G (n=48) | ETI-SF-P (n=48) | ETI-SF-E (n=48) | ETI-SF-S (N=48) | ETI-SF-T (N=48) | PANSS-P (n=50) | PANSS-N (n=50) | PANSS-G (n=50) | PANSS-T (n=50) |
|-----------|-------------|-------------|-------------|-----------------|-----------------|-----------------|-----------------|-----------------|----------------|----------------|----------------|----------------|
| CpG 1     | -0.033      | 0.907       | -0.075      | 0.705           | -0.059          | 0.900           | -0.051          | 0.830           | -0.070          | 0.831           | -0.124          | 0.708           |
| CpG 2     | -0.137      | 0.782       | -0.132      | 0.583           | -0.147          | 0.601           | 0.115           | 0.830           | -0.087          | 0.680           | -0.223          | 0.738           |
| CpG 3     | 0.022       | 0.907       | -0.137      | 0.583           | -0.037          | 0.911           | 0.069           | 0.830           | 0.063           | 0.680           | 0.044           | 0.869           |
| CpG 4     | -0.018      | 0.907       | -0.010      | 0.948           | 0.013           | 0.932           | 0.197           | 0.802           | 0.093           | 0.680           | 0.014           | 0.928           |
| CpG 5     | 0.167       | 0.782       | 0.217       | 0.387           | 0.247           | 0.363           | -0.175          | 0.802           | 0.199           | 0.531           | 0.149           | 0.738           |
| CpG 6     | 0.119       | 0.782       | 0.252       | 0.387           | 0.217           | 0.363           | -0.169          | 0.802           | 0.180           | 0.531           | 0.126           | 0.740           |
| CpG 7     | 0.172       | 0.782       | 0.242       | 0.387           | 0.240           | 0.363           | 0.010           | 0.948           | 0.262           | 0.531           | 0.168           | 0.738           |
| CpG 8     | 0.164       | 0.782       | 0.207       | 0.387           | 0.212           | 0.363           | -0.069          | 0.830           | 0.210           | 0.531           | 0.159           | 0.738           |
| Mean      | 0.059       | 0.907       | 0.106       | 0.628           | 0.104           | 0.743           | -0.072          | 0.830           | 0.157           | 0.548           | 0.098           | 0.782           |

Note: BS-E, BS-C, and BS-T: Brooding Scale-Emotion, -Cognition, and -Total; ETI-SF-G, ETI-SF-P, ETI-SF-E, ETI-SF-S, and ETI-SF-T: Early Trauma Inventory Self-Report Short Form-General, -Physical, -Emotion, -Sexual, and -Total; PANSS-P, PANSS-N, PANSS-G, and PANSS-T: Positive and Negative Syndrome Scale-Positive, -Negative, -General, and -Total. False discovery rate adjusted p value. Spearman partial correlation analysis was performed with a covariate of age, gender, and CPZ. * < 0.05, ** < 0.01, and *** < 0.001.
| CpG sites | BS-E (n=41) | BS-C (n=41) | BS-T (n=41) | ETI-SF-G (n=41) | ETI-SF-P (n=41) | ETI-SF-E (n=41) | ETI-SF-S (n=41) | ETI-SF-T (N=41) | r    | p value | r    | p value | r    | p value | r    | p value | r    | p value | r    | p value |
|-----------|-------------|-------------|-------------|----------------|----------------|----------------|----------------|----------------|-------|---------|-------|---------|-------|---------|-------|---------|-------|---------|-------|---------|
| CpG1      | 0.208       | 0.384       | 0.218       | 0.391          | 0.239          | 0.269          | 0.072          | 0.826          | 0.263 | 0.330   | 0.184 | 0.708   | 0.092 | 0.785   | 0.186 | 0.482   |
| CpG2      | -0.032      | 0.877       | -0.175      | 0.508          | -0.088         | 0.780          | 0.125          | 0.718          | 0.086 | 0.717   | -0.116 | 0.708   | 0.247 | 0.582   | 0.087 | 0.726   |
| CpG3      | 0.391*      | 0.209       | 0.169       | 0.508          | 0.333*         | 0.114          | 0.375*         | 0.279          | 0.350* | 0.216   | 0.382* | 0.245   | 0.071 | 0.834   | 0.441* | 0.075   |
| CpG4      | 0.068       | 0.852       | 0.043       | 0.852          | 0.065          | 0.780          | 0.223          | 0.678          | 0.369* | 0.216   | 0.144 | 0.708   | 0.232 | 0.582   | 0.358* | 0.190   |
| CpG5      | 0.172       | 0.493       | -0.106      | 0.601          | 0.058          | 0.780          | 0.181          | 0.678          | 0.190 | 0.461   | 0.109 | 0.708   | 0.234 | 0.582   | 0.260 | 0.482   |
| CpG6      | 0.093       | 0.784       | 0.113       | 0.601          | 0.118          | 0.714          | 0.199          | 0.678          | 0.145 | 0.568   | 0.106 | 0.708   | 0.114 | 0.785   | 0.194 | 0.482   |
| CpG7      | -0.160      | 0.496       | -0.148      | 0.521          | -0.197         | 0.384          | 0.147          | 0.718          | 0.223 | 0.390   | 0.023 | 0.940   | -0.106 | 0.785  | 0.149 | 0.611   |
| CpG8      | -0.055      | 0.853       | 0.028       | 0.864          | -0.006         | 0.972          | 0.243          | 0.678          | 0.218 | 0.390   | 0.135 | 0.708   | 0.180 | 0.753   | 0.217 | 0.482   |
| CpG9      | -0.250      | 0.384       | -0.218      | 0.391          | -0.271         | 0.204          | -0.117         | 0.718          | -0.045 | 0.785   | -0.122 | 0.708   | 0.021 | 0.898   | -0.129 | 0.651   |
| CpG10     | -0.323*     | 0.334       | -0.356*     | 0.131          | -0.377*        | 0.114          | -0.049         | 0.826          | 0.074 | 0.717   | -0.155 | 0.708   | -0.130 | 0.785  | -0.080 | 0.726   |
| CpG11     | -0.295      | 0.340       | -0.432**    | 0.045          | -0.367*        | 0.114          | -0.181         | 0.678          | 0.071 | 0.717   | -0.303 | 0.459   | 0.044 | 0.847   | -0.117 | 0.651   |
| CpG12     | -0.243      | 0.384       | -0.325*     | 0.163          | -0.335*        | 0.114          | 0.042          | 0.826          | 0.075 | 0.717   | -0.115 | 0.708   | -0.255 | 0.582   | 0.013 | 0.936   |
| CpG13     | -0.213      | 0.384       | -0.450**    | 0.045          | -0.351*        | 0.114          | 0.036          | 0.826          | 0.325* | 0.216   | -0.013 | 0.940   | -0.056 | 0.847   | 0.197 | 0.482   |
| CpG14     | -0.220      | 0.384       | -0.303      | 0.183          | -0.299         | 0.160          | -0.140         | 0.718          | 0.161 | 0.545   | 0.020 | 0.940   | -0.105 | 0.785  | -0.017 | 0.936   |
| Mean      | -0.026      | 0.877       | -0.144      | 0.521          | -0.074         | 0.780          | 0.096          | 0.767          | 0.260 | 0.330   | 0.066 | 0.861   | 0.170 | 0.753   | 0.197 | 0.482   |

Note: BS-E, -C, and -T: Brooding Scale-Emotion, -Cognition, and -Total; ETI-SF-G, -P, -E, -S, and -T: Early Trauma Inventory Self-Report Short Form-General, -Physical, -Emotion, -Sexual, and -Total. *False discovery rate adjusted p value. ‡Spearman partial correlation analysis was performed with a covariate of age and gender. *< 0.05, ‡< 0.01, and ‡< 0.001.
Correlation in DRD2 & age

(a) $R = 0.482, p = 0.001$

Correlation in DRD2 & age

(b) $R = 0.49, p = 0.001$

Figure 4: Continued.
than other subgroups of participants [13]. The CpG1, CpG2, CpG3, and CpG4 sites were exactly the same as those in our study, and the CpG6, CpG7, CpG8, and CpG9 sites corresponded to our CpG5, CpG6, CpG7, and CpG8 sites, respectively. In the Misiak et al. study [13], compared to healthy controls, methylation rates of CpG2 and CpG4 were significantly lower in patients with FEP but higher in acutely relapsed patients with SZ. Therefore, the result of methylation rate at CpG2 and CpG4 in acutely relapsed patient does match exactly with our result. In the subgroup analyses, results with SSD vs. controls were same, but results with OSSO vs. controls were different. These findings signify that our initial results were mainly driven by patients with SSD and methylation status of NR3C1 in OSSO is different from SSD. Considering that patients with psychotic disorder not otherwise specified, equivalent to OSSO, show different clinical characteristics and better outcome compared to SZ [37], a separate study on NR3C1 methylation in OSSO is warranted. Interestingly, we found a significant positive correlation between methylation at CpG5 and PANSS-N. This suggests that more severe negative symptoms are associated with reduced expression of glucocorticoid receptor. Methylation rates of NR3C1 exon 1F region are closely related to trauma exposure, adversity, nonabuse suicide, and anxiety disorders [38–42]. Thus, stress or childhood trauma may lead to HPA hyperreactivity via methylation of NR3C1, which represses NR3C1 transcription. Unfortunately, we were unable to find an association between methylation of the exon 1F region of NR3C1 and childhood

\[ R = -0.177, p = 0.228 \]

\[ R = -0.002, p = 0.989 \]

**Figure 4:** Correlations between methylation rate of DRD2 gene and (a) age in patients and (b) age in controls and between methylation rate of NR3C1 gene and (c) age in patients and (d) age in controls.
trauma or rumination, although it was significant with the uncorrected p value. It may be that recent life stress rather than childhood trauma affected the results. Notably, two studies have reported an association between NR3C1 methylation and childhood adversity in psychosis [13, 43].

This study had several limitations. As with most previous studies, we selected a few candidate regions of two genes based on relevant findings. However, the locations of the regions do not match exactly with those of previous studies, which makes direct comparison difficult. This highlights the need to measure genome-wide methylation rates using microarray or methylation sequencing methods. In addition, our participants were heterogeneous in terms of diagnosis. The effects of medication were also not fully controlled. Although we did not find significant correlations between methylation rates of the two genes and CPZ equivalent dose, there is increasing evidence that several antipsychotic drugs, with the exception of haloperidol, display demethylating properties [44–46]. Therefore, antipsychotic-naïve or -free patients should be enrolled in future studies to avoid confounding effects. Finally, our methylation values were not adjusted for variation in the proportion of cell type. In blood, DNA methylation rate between the most frequent cell types varies from 3.5% up to 42% in data from about 450,000 preselected CpGs [47]. Adjusting cellular heterogeneity has usually been applied to data measured via genome-wide analyses with Illumina BeadChip microarrays. However, considering region-specific differential DNA methylation between white blood cell subtypes [48], adjusting for proportion of cell type seems necessary for bisulfite pyrosequencing data.

Despite these caveats, our study is the first trial to measure DNA methylation rates of two key genes in individuals with RO psychosis and explore its association with childhood trauma. In addition, we carefully controlled for various confounding factors related to lifestyle behaviors such as smoking, drinking, dietary habits, and physical activity. We identified aberrant DNA methylation rates in patients with RO psychosis compared to healthy controls at several CpG sites of the NR3C1 exon 1F region but not at the target regions of DRD2. Although the functional significance of this difference in methylation is unclear, it suggests that epigenetic aberrations of NR3C1 are associated with the presence of RO psychosis and negative symptoms. Improved understanding of epigenetic liabilities would help prevent or reverse certain disease processes related to psychosis.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

All samples derived from the Korea Biobank Network were obtained with informed consent under institutional review board-approved protocols.

Conflicts of Interest

There are no known conflicts of interest associated with this publication.

Authors’ Contributions

Young-Chul Chung contributed to the conceptualization, funding, supervision, writing original draft, writing review, and editing. Yan-Hong Piao and Yin Cui contributed to the data acquisition, writing original draft, writing review, and editing. Yan-Hong Piao, Yin Cui, Fatima Zahra Rami, Ling Li, Maryam Karamikheirabad, Sung-Wan Kim, Bong Ju Lee, Jung Jin Kim, Je-Chun Yu, Kyu Young Lee, Seung-Hee Won, Seung-Hwan Lee, Seung-Hyun Kim, Shi Hyun Kang, Euitae Kim, and Nam-In Kang contributed to formal analysis.

Acknowledgments

The corresponding author would like to thank all participants in the study, as well as father for the guidance (SDG). The biospecimens and data used in this study were provided by the Biobank of Jeonbuk National University Hospital, a member of the Korea Biobank Network, which is supported by the Ministry of Health, Welfare and Family Affairs. This study was funded by the Korean Mental Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HL19C0015), and Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HI18C2383).

Supplementary Materials

Table S1: PCR primers and sequencing primers and PCR condition. Table S2–Table S6: subgroup comparison analysis. Table S7–Table S10: gender comparison analysis. Table S11–Table S19: correlation analysis. (Supplementary Materials)

References

[1] Schizophrenia Working Group of the Psychiatric Genomics Consortium, “Biological insights from 108 schizophrenia-associated genetic loci,” Nature, vol. 511, no. 7510, pp. 421–427, 2014.
[2] S. Mistry, J. R. Harrison, D. J. Smith, V. Escott-Price, and S. Zammit, “The use of polygenic risk scores to identify phenotypes associated with genetic risk of schizophrenia: systematic review,” Schizophrenia Research, vol. 197, no. 2018, pp. 2–8, 2018.
[3] M. Ghadirivsafi, S. Nohesara, H. R. Ahmadkhania et al., “Hypomethylation of the serotonin receptor type-2A gene (HTR2A) at T102C polymorphic site in DNA derived from the saliva of patients with schizophrenia and bipolar disorder,” American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, vol. 156B, no. 2011, pp. 536–545, 2011.
[4] P. A. Melas, M. Rogdaki, U. Osby, M. Schalling, C. Lavebratt, and T. J. Ekström, “Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset,” The FASEB Journal, vol. 26, no. 6, pp. 2712–2718, 2012.
[5] T. Ikegame, M. Bundo, Y. Murata, K. Kasai, T. Kato, and K. Iwamoto, "DNA methylation of the BDNF gene and its relevance to psychiatric disorders," Journal of Human Genetics, vol. 58, no. 7, pp. 434–438, 2013.

[6] M. Nishioka, M. Bundo, S. Koike et al., "Comprehensive DNA methylation analysis of peripheral blood cells derived from patients with first-episode schizophrenia," Journal of Human Genetics, vol. 58, no. 2, pp. 91–97, 2013.

[7] S. Nohesara, M. Ghadirivashchiatry, S. Mostafavi et al., "DNA hypomethylation of MB-COMT promoter in the DNA derived from saliva in schizophrenia and bipolar disorder," Journal of Psychiatric Research, vol. 45, no. 11, pp. 1432–1438, 2011.

[8] A. P. Zhang, J. Yu, J. X. Liu et al., "The DNA methylation profile within the 5′-regulatory region of DRD2 in discordant sib pairs with schizophrenia," Schizophrenia Research, vol. 90, article S0920996406004798, pp. 97–103, 2007.

[9] Y. Yoshino, K. Kawabe, T. Mori et al., "Low methylation rates of dopamine receptor D2 gene promoter sites in Japanese schizophrenia subjects," The World Journal of Biological Psychiatry, vol. 17, no. 6, pp. 449–456, 2016.

[10] D. M. Kordi-Tamandani, S. Rahnavanard, and A. Torkamanzehi, "Analysis of association between dopamine receptor genes’ methylation and their expression profile with the risk of schizophrenia," Psychiatric Genetics, vol. 23, no. 5, pp. 183–187, 2013.

[11] Y. Yoshino, K. Kawabe, T. Mori et al., "Low methylation rates of dopamine receptor D2 gene promoter sites in Japanese schizophrenia subjects," The World Journal of Biological Psychiatry, vol. 17, no. 6, pp. 449–456, 2016.

[12] L. Liu, J. Wu, L. Qing et al., "DNA methylation analysis of the Nr3c1 gene in patients with schizophrenia," Journal of Molecular Neuroscience, vol. 70, no. 8, pp. 1177–1185, 2020.

[13] B. Misiak, I. Samochowiec, A. Konopka et al., "Clinical correlates of the NR3C1 gene methylation at various stages of psychosis," The International Journal of Neuropsychopharmacology, vol. 24, no. 4, pp. 322–332, 2021.

[14] F. Varese, S. Smeets, M. Drukker et al., "Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies," Schizophrenia Bulletin, vol. 38, no. 4, pp. 661–671, 2012.

[15] B. Labonte, V. Yerko, J. Gross et al., "Differential glucocorticoid receptor exon 1(B), 1(C), and 1(H) expression and methylation in suicide completers with a history of childhood abuse," Biological Psychiatry, vol. 72, no. 1, pp. 41–48, 2012.

[16] K. M. Radke, M. Schauer, H. M. Gunter et al., "Epigenetic modifications of the glucocorticoid receptor gene are associated with the vulnerability to psychopathology in childhood maltreatment," Translational Psychiatry, vol. 5, no. 5, article e571, 2015.

[17] D. Ribaux and L. J. Phillips, "Rumination, depressive symptoms, and awareness of illness in schizophrenia," Behavioural and Cognitive Psychotherapy, vol. 42, no. 2, article S1352465812000088, pp. 143–155, 2014.

[18] R. Halari, P. Premkumar, L. Farquharson, D. Fannon, E. Kuipers, and V. Kumari, "Rumination and negative symptoms in schizophrenia," The Journal of Nervous and Mental Disease, vol. 197, no. 9, pp. 703–706, 2009.

[19] J. C. Badcock, G. Paulik, and M. T. Maybery, "The role of emotion regulation in auditory hallucinations," Psychiatry Research, vol. 185, no. 3, pp. 303–308, 2011.

[20] Y. Cui, S. W. Kim, B. J. Lee et al., "Negative schema and rumination as mediators of the relationship between childhood trauma and recent suicidal ideation in patients with early psychosis," The Journal of Clinical Psychiatry, vol. 80, no. 3, p. 17m12088, 2019.

[21] Y. Cui, Y. Piao, S. W. Kim et al., "Psychological factors intervening between childhood trauma and suicidality in first-episode psychosis," Psychiatry Research, vol. 293, article 113465, 2020.

[22] American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Press, Arlington, Va, USA, 5th edition edition, 2013.

[23] S. R. Kay, A. Fiszbein, and L. A. Opler, "The positive and negative syndrome scale (PANSS) for schizophrenia," Schizophrenia Bulletin, vol. 13, no. 2, pp. 261–276, 1987.

[24] J. S. Yi, Y. M. Ahn, H. K. Shin et al., "Reliability and validity of the Korean version of the positive and negative syndrome scale," Journal of Korean Neuropsychiatric Association, vol. 40, no. 6, pp. 1090–1105, 2001.

[25] D. Addington, J. Addington, and B. Schissel, "A depression rating scale for schizophrenics," Schizophrenia Research, vol. 3, no. 4, article 09209964900005R, pp. 247–251, 1990.

[26] Y. K. Kim, S. D. Won, K. M. Lee et al., "A study on the reliability and validity of the Korean version of the Calgary depression scale for schizophrenia (K-CDSS)," Journal of Korean Neuropsychiatric Association, vol. 44, no. 4, pp. 446–455, 2005.

[27] J. H. Kim, Y. Piao, W. S. Kim et al., "The development of the brooding scale," Psychiatry Investigation, vol. 16, no. 6, pp. 443–449, 2019.

[28] J. D. Bremner, R. Bolus, and E. A. Mayer, "Psychometric properties of the early trauma inventory-self report," The Journal of Nervous and Mental Disease, vol. 195, no. 3, pp. 211–218, 2007.

[29] T. F. Heatherton, L. T. Kozlowski, R. C. Frecker, and K. O. Fagerstrom, "The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire," British Journal of Addiction, vol. 86, no. 9, pp. 1119–1127, 1991.

[30] J. S. Kim, M. K. Oh, B. K. Park, M. K. Lee, and G. J. Kim, "Screening criteria of alcoholism by alcohol use disorders identification test (AUDIT) in Korea," Journal of the Korean Academy of Family Medicine, vol. 20, no. 9, pp. 1152–1159, 1999.

[31] M. Jhon, T. Yoo, J. Y. Lee et al., "Gender-specific risk factors for low bone mineral density in patients taking antipsychotics for psychosis," Human Psychopharmacology, vol. 33, no. 1, p. 10, 2018.

[32] A. S. Jackson, S. N. Blair, M. T. Mahar, L. T. Wier, R. M. Ross, and J. E. Stuteville, "Prediction of functional aerobic capacity without exercise testing," Medicine and Science in Sports and Exercise, vol. 22, no. 6, pp. 863–870, 1990.

[33] N. P. Daskalakis and R. Yehuda, "Site-specific methylation changes in the glucocorticoid receptor exon 1F promoter in relation to life adversity: systematic review of contributing factors," Frontiers in Neuroscience, vol. 8, p. 369, 2014.

[34] O. Fornes, J. A. Castro-Mondragon, A. Khan et al., "JASPAR 2020: update of the open-access database of transcription factor binding profiles," Nucleic Acids Research, vol. 48, no. D1, pp. D87–D92, 2020.

[35] R. Engeland and M. Pettersson, "Pyro Q-CpG™: quantitative analysis of methylation in multiple CpG sites by Pyrosequencing™," Nature Methods, vol. 2, no. 10, pp. i–ii, 2005.

[36] J. van Dongen, M. J. Bonder, K. F. Dekkers et al., "DNA methylation signatures of educational attainment," NPJ Sci Learn, vol. 3, no. 1, article 20, p. 7, 2018.
[37] L. Li, F. Z. Rami, Y. H. Piao et al., "Comparison of clinical features and 1-year outcomes between patients with psychotic disorder not otherwise specified and those with schizophrenia," *Early Intervention in Psychiatry*, 2022.

[38] A. R. Tyrka, S. H. Parade, E. S. Welch et al., "Methylation of the leukocyte glucocorticoid receptor gene promoter in adults: associations with early adversity and depressive, anxiety and substance-use disorders," *Translational Psychiatry*, vol. 6, no. 7, article e848, 2016.

[39] R. Schur, M. Boks, B. Rutten et al., "Longitudinal Changes in Glucocorticoid Receptor Exon 1F Methylation as a Biomarker for Psychopathology After Military Deployment," *Translational Psychiatry*, vol. 83, no. 9, article e1181, p. S91, 2018.

[40] P. O. McGowan, A. Sasaki, A. C. D’Alessio et al., "Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse," *Nature Neuroscience*, vol. 12, no. 3, pp. 342–348, 2009.

[41] W. Wang, J. Feng, C. Ji et al., "Increased methylation of glucocorticoid receptor gene promoter 1F in peripheral blood of patients with generalized anxiety disorder," *Journal of Psychiatric Research*, vol. 91, pp. 18–25, 2017.

[42] B. Roy, R. C. Shelton, and Y. Dwivedi, "DNA methylation and expression of stress related genes in PBMC of MDD patients with and without serious suicidal ideation," *Journal of Psychiatric Research*, vol. 89, pp. 115–124, 2017.

[43] V. Barker, R. M. Walker, K. L. Evans, and S. M. Lawrie, "Methylation of glucocorticoid receptor (NR3C1), BDNF and oxytocin receptor genes in association with childhood maltreatment in schizophrenia and schizoaffective disorder," *Schizophrenia Research*, vol. 216, pp. 529–531, 2020.

[44] A. Guidotti and D. R. Grayson, "DNA methylation and demethylation as targets for antipsychotic therapy," *Dialogues in Clinical Neuroscience*, vol. 16, no. 3, pp. 419–429, 2014.

[45] M. G. Melka, C. A. Castellani, B. I. Laufer, N. Rajakumar, R. O’Reilly, and S. M. Singh, "Olanzapine induced DNA methylation changes support the dopamine hypothesis of psychosis," *J. Mol. Psychiatry*, vol. 1, no. 1, p. 19, 2013.

[46] H. Sugawara, M. Bundo, J. Ishigooka, K. Iwamoto, and T. Kato, "Epigenetic regulation of serotonin transporter in psychiatric disorders," *Journal of Genetics and Genomics*, vol. 40, no. 7, pp. 325–329, 2013.

[47] L. E. Reinius, N. Acevedo, M. Joerink et al., "Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility," *PLoS One*, vol. 7, no. 7, article e41361, 2012.

[48] B. T. Adalsteinsson, H. Gudnason, T. Aspeland et al., "Heterogeneity in white blood cells has potential to confound DNA methylation measurements," *PLoS One*, vol. 7, no. 10, article e46705, 2012.